1. Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice
- Author
-
Jeffrey D. Macklis, Jessica L. MacDonald, Noriyuki Kishi, Bradley J. Molyneaux, Eiman Azim, and Julia Ye
- Subjects
Male ,0301 basic medicine ,congenital, hereditary, and neonatal diseases and abnormalities ,Methyl-CpG-Binding Protein 2 ,Science ,General Physics and Astronomy ,Rett syndrome ,Biology ,Article ,General Biochemistry, Genetics and Molecular Biology ,MECP2 ,Mice ,03 medical and health sciences ,Neurodevelopmental disorder ,Downregulation and upregulation ,mental disorders ,Rett Syndrome ,medicine ,Animals ,Mice, Knockout ,Regulation of gene expression ,Multidisciplinary ,NF-kappa B ,General Chemistry ,medicine.disease ,Phenotype ,3. Good health ,nervous system diseases ,Interleukin-1 Receptor-Associated Kinases ,030104 developmental biology ,medicine.anatomical_structure ,Gene Expression Regulation ,Cerebral cortex ,Immunology ,Female ,Signal transduction ,Neuroscience ,Signal Transduction - Abstract
Mutations in the transcriptional regulator Mecp2 cause the severe X-linked neurodevelopmental disorder Rett syndrome (RTT). In this study, we investigate genes that function downstream of MeCP2 in cerebral cortex circuitry, and identify upregulation of Irak1, a central component of the NF-κB pathway. We show that overexpression of Irak1 mimics the reduced dendritic complexity of Mecp2-null cortical callosal projection neurons (CPN), and that NF-κB signalling is upregulated in the cortex with Mecp2 loss-of-function. Strikingly, we find that genetically reducing NF-κB signalling in Mecp2-null mice not only ameliorates CPN dendritic complexity but also substantially extends their normally shortened lifespan, indicating broader roles for NF-κB signalling in RTT pathogenesis. These results provide new insight into both the fundamental neurobiology of RTT, and potential therapeutic strategies via NF-κB pathway modulation., Rett syndrome is a neurodevelopmental disorder caused by mutations in Mecp2. Here the authors show that Mecp2 loss-of-function leads to upregulation of the NF-κB pathway, and that reducing NF-κB signalling ameliorates phenotypes of Mecp2-null mice, thus offering a potential therapeutic strategy.
- Published
- 2016